AUTHORS
Ai Guan, MD, Yi Xu Jr, PhD2, Xinyi Xiong, MD3, Chengyang Xu4, Lu Zhang, M.D.5, Zhuang Tian, MD6, Kaini Shen, MD7, Jian Li, MD8
AFFILIATIONS
1 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
6 Peking Union Medical College Hospital, Beijing, China
7 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
8 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
ABSTRACT
Background:
The t(11;14) translocation, present in approximately 50% of patients with light-chain (AL) amyloidosis, confers poor responses to standard bortezomib-based regimens. However, this genetic alteration drives B-cell lymphoma 2 (BCL-2) dependence, making venetoclax a rational targeted therapy. While venetoclax has demonstrated encouraging activity in relapsed/refractory t(11;14) AL amyloidosis, its efficacy and safety as a frontline agent remain undefined. We report the preliminary results of a prospective phase 2 study (NCT06629818) evaluating daratumumab combined with venetoclax and dexamethasone (Dara-VenD) as initial therapy for newly diagnosed t(11;14) AL amyloidosis.
Method:
This prospective, single-arm phase 2 trial enrolled adults with newly diagnosed AL amyloidosis, t(11;14) positivity (≥10% by fluorescence in situ hybridization), and a difference between involved and uninvolved serum free light chains (dFLC) >50 mg/L. The study was approved by the Institutional Review Board of Peking Union Medical College Hospital (I 24PJ1989) and conducted in accordance with the Declaration of Helsinki. Patients received up to 12 28-day cycles of oral venetoclax (400 mg daily), subcutaneous daratumumab (1800 mg; weekly for cycles 1-2, biweekly for cycles 3-6, and monthly thereafter), and dexamethasone (20 mg weekly; reduced to 10 mg after cycle 6). Hematologic and organ responses were assessed monthly for the first 3 months, then every 3 months. Discontinuation criteria included intolerance, progression, or refractory disease (<partial response [PR] after cycle 1 or <very good partial response [VGPR] after cycle 3). The primary endpoint was the 3-month complete response (CR) plus VGPR rate.
Results:
Between October 2024 and April 2026, 38 patients were enrolled (median follow-up: 10.9 months). Baseline demographics included a median age of 61 years (IQR 54-70), and 71.1% were male. Organ involvement included the heart (86.8%), kidney (60.5%), liver (13.2%), and gastrointestinal tract (10.5%). Modified Mayo 2004 stages were I (18.4%), II (60.5%), IIIA (18.4%), and IIIB (2.6%). The median dFLC was 396.7 mg/L (78.9% having dFLC ≥180 mg/L), with a median t(11;14) clone size of 66% and median bone marrow plasma cells of 7%. Hematologic response kinetics were exceptionally rapid and deep. The 3-month CR+VGPR rate, which served as the primary endpoint, was 88.6% (CR 54.3%), thereby achieving the primary endpoint. Longitudinal assessment showed a 1-month CR+VGPR of 76.3% (CR 42.1%), 6-month of 85.7% (CR 60.7%), and 12-month of 77.3% (CR 63.6%). The best overall CR+VGPR rate achieved was 89.5% (best CR 68.4%), with a 100% overall response rate (ORR). Organ responses deepened progressively over time. Among evaluable patients at 6 and 12 months, cardiac ORRs were 58.3% (14/24) and 70.6% (12/17), respectively. Renal ORRs at 6 and 12 months were 52.6% (10/19) and 80.0% (12/15), respectively. The best overall cardiac and renal response rates across the entire cohort were 51.5% (17/33) and 69.6% (16/23). The safety profile was manageable. Grade 3/4 adverse events were primarily hematologic, dominated by lymphopenia (23.7%), anemia (2.6%), with no grade 3/4 neutropenia observed. Non-hematologic grade 3/4 events included pneumonia and diarrhea (2.6% each). Five patients discontinued treatment: 3 due to cardiac death (all within the first 3 months), 1 due to hepatic failure (also resulted in death), and 1 due to unsatisfactory efficacy. No additional deaths occurred during follow-up.
Conclusion:
The Dara-VenD regimen is highly active as frontline therapy for t(11;14) AL amyloidosis. It induces profound and rapid hematologic responses along with promising, progressively deepening organ responses. The safety profile is favorable, with early mortality restricted to advanced baseline disease. These preliminary results strongly support the continued investigation of this biomarker-driven, targeted combination in this population.
DISCLOSURES
Ai Guan, MD: No relevant conflicts of interest to declare.